This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Potassium hydrogen DL-aspartate is a medication indicated to treat combined potassium-magnesium deficiency with subsequent arrhythmia.
- Generic Name
- Potassium hydrogen DL-aspartate
- DrugBank Accession Number
- DB15998
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Potassium hydrogen DL-aspartate (DB15998)
- Weight
- Average: 171.193
Monoisotopic: 170.99338917 - Chemical Formula
- C4H6KNO4
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Arrhythmia caused by combined magnesium and potassium deficiency Combination Product in combination with: Magnesium aspartate (DB13359) •••••••••••• •••••••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Trommcardin - Filmtabletten Potassium hydrogen DL-aspartate (360 mg) + Magnesium aspartate (360 mg) Tablet, film coated Oral Jacoby Gm Pharma Gmb H 1972-04-11 Not applicable Austria 
Trommcardin K 120 - Infusionsflasche Potassium hydrogen DL-aspartate (30 mmol) + Magnesium aspartate (7.5 mmol) Injection, solution Intravenous Jacoby Gm Pharma Gmb H 1978-01-16 Not applicable Austria
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 5UW00M8KR0
- CAS number
- 923-09-1
- InChI Key
- TXXVQZSTAVIHFD-UHFFFAOYSA-M
- InChI
- InChI=1S/C4H7NO4.K/c5-2(4(8)9)1-3(6)7;/h2H,1,5H2,(H,6,7)(H,8,9);/q;+1/p-1
- IUPAC Name
- potassium 3-amino-3-carboxypropanoate
- SMILES
- [K+].NC(CC([O-])=O)C(O)=O
References
- General References
- External Links
- ChemSpider
- 19957263
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, film coated Oral Injection, solution Intravenous - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 515.0 mg/mL ALOGPS logP -2.8 ALOGPS logP -3.5 Chemaxon logS 0.48 ALOGPS pKa (Strongest Acidic) 1.7 Chemaxon pKa (Strongest Basic) 9.61 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 103.45 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 37.37 m3·mol-1 Chemaxon Polarizability 10.99 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at December 10, 2020 20:26 / Updated at May 05, 2021 20:32